Greetings and welcome to the Incyte fourth-quarter 2024 and full-year financial and corporate update conference call webcast. (Operator Instructions) As a reminder, this conference is being recorded.

Vertex provided 2025 revenue guidance of $11.75 billion to $12 billion, reflecting 8% growth at the midpoint. Growth is expected from U.S. launches of ALYFTREK and JOURNAVX, along with the continued ...

Operator Good day, and welcome to the Vertex Pharmaceuticals fourth quarter 2024 earnings call. All participants will be in a ...